Business Context and Reporting Period
This Form 8-K filing by Signal Genetics, Inc. (not Viridian Therapeutics, Inc.) reports on a Special Meeting of stockholders held on February 10, 2017. The filing details the voting results for ten proposals related to a merger, corporate restructuring, and asset sales.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or margins. The only specific financial figure disclosed is the principal amount of an Unsecured Demand Promissory Note issued to Bennett LeBow, which was $1,105,009.
Material Changes and Voting Results
Stockholders representing approximately 58.05% of outstanding common stock (430,919 shares) voted on the following proposals. All proposals were approved:
- Merger Approval: Approved the merger with Miragen Therapeutics, Inc. (416,151 For vs. 4,653 Against).
- Change in Control: Approved the resulting change in control (416,284 For vs. 4,440 Against).
- Note Conversion: Approved converting the $1,105,009 promissory note into common stock (419,433 For vs. 1,391 Against).
- Equity Plans: Approved the 2016 Equity Incentive Plan and 2016 Employee Stock Purchase Plan.
- Corporate Name Change: Approved changing the corporate name to "Miragen Therapeutics, Inc." (416,300 For vs. 4,507 Against).
- Reverse Stock Split: Approved a reverse stock split within a range of 1-to-15 shares (415,398 For vs. 5,409 Against).
- Authorized Shares: Approved increasing authorized common stock from 50,000,000 to 100,000,000 shares (417,040 For vs. 3,767 Against).
- Asset Sale: Approved the sale of intellectual property assets related to the MyPRS test to Quest Diagnostics Investments LLC (415,559 For vs. 5,202 Against).
- Governance Change: Approved eliminating the ability of stockholders to act by written consent (398,063 For vs. 22,491 Against).
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the context of the merger and asset sale. The primary event is the execution of the Merger Agreement dated October 31, 2016, and the divestiture of the MyPRS test assets.
Investor Verification Checklist
- Verify the final ratio of the reverse stock split, as the filing only approved a range of 1-to-15.
- Confirm the closing date and terms of the merger with Miragen Therapeutics, Inc.
- Review the definitive terms of the Intellectual Property Purchase Agreement with Quest Diagnostics Investments LLC regarding the MyPRS test.
- Check subsequent filings for the exact number of shares issued upon conversion of the Bennett LeBow promissory note.